Surgical treatment of peritoneal carcinomatosis from gastric cancer
- PMID: 22778938
- PMCID: PMC3388312
- DOI: 10.1155/2012/405652
Surgical treatment of peritoneal carcinomatosis from gastric cancer
Abstract
Peritoneal carcinomatosis from gastric cancer is considered a fatal disease with limited treatment options. Recent advances in the understanding of the disease process, systemic chemotherapy, and application of cytoreductive surgery and hyperthermic chemoperfusion have shown promising results in the management of this difficult disease. Novel therapies such as extensive intraperitoneal lavage and intraperitoneal targeted agents are being applied in the management of this disease. We review the current literature in this field and describe the rationale behind some of these advances.
Figures
References
-
- Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. Journal of Clinical Epidemiology. 2003;56(1):1–9. - PubMed
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. Ca-A Cancer Journal for Clinicians. 2006;56(2):106–130. - PubMed
-
- Yonemura Y, Endou Y, Sasaki T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. European Journal of Surgical Oncology. 2010;36(12):1131–1138. - PubMed
-
- Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. Journal of Clinical Oncology. 2002;20(8):1996–2004. - PubMed
-
- Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine. 2006;355(1):11–20. - PubMed
LinkOut - more resources
Full Text Sources
